Do ribosomal traffic jams cause Huntington’s disease?
Huntington's disease, or HD, a genetic disorder that affects about one in every 10,000 people in the U.S., is inherited in an autosomally dominant manner, meaning that a person with the condition has a 50% chance of passing it on to their child. HD kills important neurons in the brain, causing uncontrollable movements and cognitive and psychiatric changes.
While scientists have long known that HD is caused by a cytosine–adenine–guanine trinucleotide repeat in the Huntingtin gene contained on chromosome 4, they are still studying the biological mechanisms that guide the disease process. In particular, researchers have implicated mitochondrial dysfunction in the pathophysiology of HD, and it is an ongoing focus of study.
Investigators at the Wertheim University of Florida Scripps Research Institute recently used novel techniques to examine mRNA translation within the mitochondria of mice genetically altered to have HD. They found that ribosomes — particles responsible for creating proteins from instructions encoded in mRNA — get clustered and jammed on mitochondrial mRNA transcripts. The team published these , in the journal ͵͵ & Cellular Proteomics.
Srinivasa Subramaniam, an associate professor at Wertheim UF Scripps, was the lead author on the study. “Imagine going from Baltimore to Washington, D.C., and there are too many cars, and they are all jammed up,” he said. “Just because there are many cars does not mean they are all reaching their destination.
“So, what does that mean for the patient? That means that the patient may have difficulty translating their mitochondrial protein. And that may lead to problems in the assembly of these complexes, which may lead to problems in mitochondrial function.”
This project followed from Subramaniam’s previous work, which demonstrated high expression of fragile X messenger ribonucleoprotein, or FMRP, a protein that blocks ribosomes in HD. Consequently, he was curious to see the spatial distribution of ribosomes on mitochondrial mRNA, so Subramaniam turned to a technique called Ribo-Seq, which provides a snapshot of the location and density of ribosomes on a given mRNA transcript. He had no experience with the technique and immediately faced challenges.
“I am a biochemist by training,” Subramaniam said. “So I needed to sit and write hundreds of emails like ‘Can you help me?’ all over the world.”
He connected with collaborators in France and Ireland and took on a postdoc with Ribo-Seq experience. Almost four years later, Subramaniam and his lab published the results of their work. And with these results come new questions.
Previous research has shown that deleting the FMRP protein can prevent some cognitive deficits observed in HD. Subramaniam wants to investigate how modulating the expression of FMRP can affect the spatial distribution of ribosomes on mRNA transcripts. He also wants to see how communication between the cytoplasm and mitochondria contributes to what he likens to a "traffic jam." He hypothesizes that the cytoplasm inhibits proper functioning of mitochondrial mRNA, creating confusion.
“Imagine if you are traveling through a tunnel, and you close that tunnel,” he said. “Who puts on that brake? Who triggered that pathway? What is the signal that makes this traffic jam? That is what I want to know in more detail at the molecular level.”
He hopes this work has practical applications as well.
“How can we use small-molecule screening to reverse this phenotype?” he said. “My goal is to identify the mechanisms and then leverage potential therapeutics.”
Enjoy reading ASBMB Today?
Become a member to receive the print edition four times a year and the digital edition weekly.
Learn moreGet the latest from ASBMB Today
Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.
Latest in Science
Science highlights or most popular articles
Quantifying how proteins in microbe and host interact
“To develop better vaccines, we need new methods and a better understanding of the antibody responses that develop in immune individuals,” author Johan Malmström said.
Leading the charge for gender equity
Nicole Woitowich will receive the ASBMB Emerging Leadership Award at the 2025 ASBMB Annual meeting, April 12–15 in Chicago.
CRISPR gene editing: Moving closer to home
With the first medical therapy approved, there’s a lot going on in the genome editing field, including the discovery of CRISPR-like DNA-snippers called Fanzors in an odd menagerie of eukaryotic critters.
Finding a missing piece for neurodegenerative disease research
Ursula Jakob and a team at the University of Michigan have found that the molecule polyphosphate could be what scientists call the “mystery density” inside fibrils associated with Alzheimer’s, Parkinson’s and related conditions.
From the journals: JLR
Enzymes as a therapeutic target for liver disease. Role of AMPK in chronic liver disease Zebrafish as a model for retinal dysfunction. Read about the recent JLR papers on these topics.
Computational and biophysical approaches to disordered proteins
Rohit Pappu will receive the 2025 DeLano Award for Computational Biosciences at the ASBMB Annual Meeting, April 12-15 in Chicago.